2015
DOI: 10.1002/humu.22930
|View full text |Cite
|
Sign up to set email alerts
|

A Newly Identified Missense Mutation inFARS2Causes Autosomal-Recessive Spastic Paraplegia

Abstract: Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by spasticity of the lower limbs due to pyramidal tract dysfunction. Here, we report that a missense homozygous mutation c.424G>T (p.D142Y) in the FARS2 gene, which encodes a mitochondrial phenylalanyl tRNA synthetase (mtPheRS), causes HSP in a Chinese consanguineous family by using combination of homozygous mapping and whole-exome sequencing. Immunohistochemical experiments were… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
31
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 50 publications
(32 citation statements)
references
References 24 publications
1
31
0
Order By: Relevance
“…Our subject possessed novel compound heterozygous mutations in FARS2 (Q216X and P136H) resulting in a pure spastic paraplegia syndrome that was also associated with bilateral signal abnormalities of the dentate nuclei. His phenotype was similar to a previously reported consanguineous Chinese family with pure spastic paraplegia due to homozygous mutations within the catalytic domain of mtPheRS (D142Y), although their neuroimaging was normal . To date, these subjects represent the mildest cases of FARS2 ‐related disease.…”
Section: Discussionsupporting
confidence: 83%
See 1 more Smart Citation
“…Our subject possessed novel compound heterozygous mutations in FARS2 (Q216X and P136H) resulting in a pure spastic paraplegia syndrome that was also associated with bilateral signal abnormalities of the dentate nuclei. His phenotype was similar to a previously reported consanguineous Chinese family with pure spastic paraplegia due to homozygous mutations within the catalytic domain of mtPheRS (D142Y), although their neuroimaging was normal . To date, these subjects represent the mildest cases of FARS2 ‐related disease.…”
Section: Discussionsupporting
confidence: 83%
“…More moderate phenotypes consisting of cognitive disability, motor delays, and epilepsy have also been reported . In its mildest form, FARS2 presented with a pure spastic paraplegia syndrome in a consanguineous Chinese family with homozygous mutations (spastic paraplegia type 77; SPG77 MIM#617046) …”
Section: Introductionmentioning
confidence: 99%
“…We also coded PavCA index score as a 233 binary trait using various thresholds to define cases (goal-trackers) and controls (sign-trackers); 234 this approach identified two genome-wide significant associations. The first locus was unique to Fars2 (Page 68 in S1 File; Fig 4B), a mitochondrial phenylalanyl-tRNA synthetase involved in 240 oxidative phosphorylation and neuronal functioning [31][32][33]. We then expanded our search to the average of days 4 and 5 for each of the 10 remaining 252 metrics individually.…”
mentioning
confidence: 99%
“…This locus was identified for multiple 343 metrics on days 4 and 5, as well as in the univariate analysis of the first PC from PCA on the 344 comprehensive set of all 55 metrics. All genome-wide significant SNPs were located in an intron 345 of Fars2 (Fig3B), which is highly expressed in the Purkinje cells of the cerebellum [31] but has 346 no previously known ties to behavior. Another promising locus for magazine entries and latency 347 to magazine entry during CS presentation was on chromosome 1.…”
mentioning
confidence: 99%
“…To date at least 21 pathogenic variants have been reported for HsmitPheRS that were found to be associated with disease conditions with moderate to severe symptoms. The clinical phenotypic expression of the pathogenic variants of the FARS2 gene show pleiotropic effects, from spastic paraplegia to infantile Alpers encephalopathy (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). The effects of some of these mutations on enzyme function have been investigated.…”
Section: Introductionmentioning
confidence: 99%